Key result
Risk stratification in Brugada syndrome remains challenging, with genetic testing identifying disorders in only 20-30% of patients, highlighting the need for improved sudden cardiac death prevention.
Why the study?
Risk stratification in Brugada syndrome is challenging, leading to failure to provide appropriate sudden cardiac death prevention strategies for many patients.
This review highlights the challenges in risk stratification for Brugada syndrome and summarizes contemporary evidence to improve sudden cardiac death prevention.
Challenges in Brugada syndrome risk stratification warrant clinical caution; leaves open improved sudden cardiac death prevention strategies.
Brugada syndrome (BrS) is an inherited disease with an increased risk of sudden cardiac death (SCD). However, testing identifies genetic disorders in only 20-30% of patients analysed, indicating a gap in knowledge of its genetic aetiology. Diagnosis relies on ECG, and risk stratification in BrS patients is challenging, primarily because of the complexity of the issue. As a result, clinicians fail to provide the appropriate strategy for SCD prevention for many patients. Several variables and interventions are being studied to improve diagnostics and maximise patient protection. In addition, the scientific community must increase efforts to provide patient care according to knowledge and research for improving stratification of risk. In this article, the authors summarise contemporary evidence on clinical variables and provide an overview of future directions in risk stratification and SCD prevention.
No takes yet. Share an insight, caveat, or question.
Iglesias et al. (2019) conducted a review in Brugada syndrome. Risk stratification in Brugada syndrome remains challenging, with genetic testing identifying disorders in only 20-30% of patients, highlighting the need for improved sudden cardiac death prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: